Sullivan, R. J., Infante, J. R., Janku, F., Wong, D. J. L., Sosman, J. A., Keedy, V., . . . Li, B. T. (2018). First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer discovery, 8(2), 184. https://doi.org/10.1158/2159-8290.CD-17-1119
Citace podle Chicago (17th ed.)Sullivan, Ryan J., et al. "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study." Cancer Discovery 8, no. 2 (2018): 184. https://doi.org/10.1158/2159-8290.CD-17-1119.
Citace podle MLA (9th ed.)Sullivan, Ryan J., et al. "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study." Cancer Discovery, vol. 8, no. 2, 2018, p. 184, https://doi.org/10.1158/2159-8290.CD-17-1119.